Citadel Advisors’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Citadel Advisors’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,214	Closed	-$202K	–	10190
2019 Q3	$202K	Sell	7,214 -115,825	-94%	-$1.88M	﹤0.01%	8148
2019 Q2	$1.73M	Buy	123,039 +77,532	+170%	+$737K	﹤0.01%	4761
2019 Q1	$405K	Buy	45,507 +5,860	+15%	+$47.6K	﹤0.01%	7144
2018 Q4	$301K	Buy	+39,647	New	+$638K	﹤0.01%	7270
2018 Q3	–	Sell	-7,493	Closed	-$224K	–	9978
2018 Q2	$224K	Buy	+7,493	New	+$204K	﹤0.01%	7698

Citadel Advisors's DOVA Position: Q4 2019 in Review

Citadel Advisors sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 7,214 shares — an estimated $202K sold.

Citadel Advisors first reported a position in DOVA in Q2 2018 and held it in 5 quarters. The position peaked at $1.73M in Q2 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

Citadel Advisors reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Citadel Advisors sold 7,214 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $202K.
Citadel Advisors first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Citadel Advisors's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.73M in Q2 2019.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.